It was a pleasure to speak with Bob Geng (University of California, San Diego, CA, USA) to give us an overview of immunoglobulin replacement therapy, and subcutaneous human IgG 16.5% in patients with immunodeficiencies.
The abstract entitled ‘Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies‘ (ABSTRACT NUMBER: 238) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Part 2 of our discussion can be viewed here.
Questions:
1. Could you give us a brief overview of immunoglobulin replacement therapy in patients with primary immunodeficiencies? (0:18)
2. What are the advantages and limitations of subcutaneous human IgG 16.5% compared with other IgG formulations? (1:48)
Disclosures: Consultant and speaker for Takeda and Grifols; consultant for Koru and Kedrion; provided clinical trial support for Octapharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
